SELLAS Life Sciences Group Inc. (SLS) is a late-stage clinical biopharmaceutical company focusing on the production of innovative cancer immunotherapies for a wider variety of indications of cancer. And today, in absence of any significant news directly linked to the company, the company’s stock has been skyrocketing more than 67% in pre-market trades at a price of $13.70 (07:44 a.m. EST).
GPS, the lead product candidate of SELLAS, is approved by the Memorial Sloan Kettering Cancer Center and targets the WT1 protein found in a number of types of tumors. GPS has the ability to treat a full range of hematologic malignancies and solid tumor indications as a monotherapy or in combination. The second candidate of SELLAS, NPS, is HER2-directed immunotherapy for cancer that has the ability to treat patients with early-stage breast cancer with low to moderate HER2 expression, better known as HER2 1+ or 2+, and includes patients with triple-negative breast cancer following standard care.
- Top 3 Cloud Computing Stocks to Watch For in 2021
- 3 Best Work-From-Home Stocks for Long-term Investment
The shares of the company might be soaring helped by its standing among major players on The Global Wilms Tumor Protein Sales 2021 market research report released this week.
A basic overview of the sector, including concepts, classifications, applications, and industry chain structure, is provided by the Global Wilms Tumor Protein Sales 2021 market report. The global market share analysis of Wilms Tumor Protein sales is presented for foreign markets, including growth patterns, competitive landscape analysis, and development status of key regions. As well as manufacturing strategies and cost structures, construction policies and proposals are discussed. This ratio also displays consumption, supply and demand, statistics, rates, sales, profits, and gross margins for import/export. This report analyzes the Wilms Tumor protein production locations, revenue, capability, output, ex-factory prices, for each producer covered.
Despite the mentioned news, the stock has been under discussion at the Reddit “WallStreetBets” which was also the reason behind the 400% rise in GameStop shares last week. Users on the platform have been noting that despite the organization recently highlighting the production of innovative cancer immunotherapies, Sellas is considered undervalued and firmly shortened.